Osivelotor

Generic Name: Osivelotor

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₂O_₆

CAS Number: 2417955-18-9

Unique Ingredient Identifier: UK749B4S16

Associated Conditions: -

Associated Therapies: -

Clinical Trials

5 Sickle Cell Therapies to Watch Following Pfizer's Oxbryta Exit

Pfizer's withdrawal of Oxbryta from global markets due to increased risk of deaths and complications has left the sickle cell disease community reeling. Despite recent setbacks, hope for SCD treatment lies in next-gen transplantation and gene therapy, with St. Jude developing its own gene therapy. Pfizer's inclacumab and osivelotor, Agios Pharmaceuticals' mitapivat, Novo Nordisk's etavopivat, and Fulcrum Therapeutics' pociredir are among investigational therapies in the SCD pipeline.

Related Clinical Trials:

A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

A Phase 2/3 Study in Adult and Pediatric Participants With SCD

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

biopharmadive.com

3 months ago

Pfizer to pull sickle cell drug from market, shut down trials

Pfizer is withdrawing Oxbryta, a sickle cell disease drug, due to safety concerns, leading to an imbalance of deaths and vaso-occlusive crises. The European Medicines Agency recommended suspending its clearance. Pfizer acquired Oxbryta through its purchase of Global Blood Therapeutics in 2022, with Oxbryta generating $92 million in revenue in Q2 2024. Pfizer continues to develop other sickle cell treatments, including inclacumab and osivelotor in Phase 3. Patients currently on Oxbryta should consult their doctors for alternatives.